AAM Succeeds As California Court Temporarily Blocks Pay-For-Delay Law
Court ‘Cannot Reasonably Find’ That Bill Regulates California Commerce Alone
A judge in California has agreed to instate a temporary injunction against a state law designed to curb so-called ‘pay-for-delay’ deals, handing victory to generics and biosimilars industry association the AAM.
You may also be interested in...
Minnesota is the latest US state to find itself facing generic drug trade group the Association for Accessible Medicines in court, after the organization filed a lawsuit alleging that its new drug pricing legislation is unconstitutional.
Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises.
‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’